Ensign Peak Advisors
NTLA icon

Ensign Peak Advisors’s Intellia Therapeutics NTLA Stock Holding History

Ensign Peak Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
9,569
+1,500
+19% +$21K ﹤0.01% 1473
2026
Q1 		$103K Hold
8,069
– – ﹤0.01% 1559
2025
Q4 		$72.5K Sell
8,069
-13,350
-62% -$184K ﹤0.01% 1631
2025
Q3 		$370K Sell
21,419
-17,750
-45% -$219K ﹤0.01% 1513
2025
Q2 		$367K Hold
39,169
– – ﹤0.01% 1627
2025
Q1 		$278K Hold
39,169
– – ﹤0.01% 1650
2024
Q4 		$457K Buy
39,169
+1,100
+3% +$17.2K ﹤0.01% 1625
2024
Q3 		$782K Buy
38,069
+2,050
+6% +$47.3K ﹤0.01% 1453
2024
Q2 		$806K Buy
36,019
+6,850
+23% +$163K ﹤0.01% 1418
2024
Q1 		$802K Sell
29,169
-1,471
-5% -$40.9K ﹤0.01% 1462
2023
Q4 		$934K Hold
30,640
– – ﹤0.01% 1425
2023
Q3 		$969K Hold
30,640
– – ﹤0.01% 1228
2023
Q2 		$1.25M Hold
30,640
– – ﹤0.01% 1086
2023
Q1 		$1.14M Hold
30,640
– – ﹤0.01% 1138
2022
Q4 		$1.07M Buy
30,640
+13,900
+83% +$661K ﹤0.01% 1107
2022
Q3 		$937K Sell
16,740
-77,677
-82% -$4.82M ﹤0.01% 1104
2022
Q2 		$4.89M Buy
94,417
+78,277
+485% +$3.97M 0.01% 547
2022
Q1 		$1.17M Hold
16,140
– – ﹤0.01% 1109
2021
Q4 		$1.91M Buy
+16,140
New +$2.02M ﹤0.01% 978

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Ensign Peak Advisors's NTLA Position: Q2 2026 in Review

Ensign Peak Advisors increased its Intellia Therapeutics (NTLA) stake by 19% in Q2 2026, buying an estimated $21K and bringing the position to 9,569 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

Ensign Peak Advisors first reported a position in NTLA in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.89M in Q2 2022. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Ensign Peak Advisors held 9,569 shares of Intellia Therapeutics worth $162K as of Q2 2026.
  • Ensign Peak Advisors bought 1,500 Intellia Therapeutics shares in Q2 2026, an estimated $21K.
  • Intellia Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1473 holding.
  • Ensign Peak Advisors first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Ensign Peak Advisors's Intellia Therapeutics position peaked at $4.89M in Q2 2022.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.